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	 Three	accurate,	sensitive	and	time	saving	spectrophotometric	methods	have	been	developed
and	validated	for	determination	of	mixture	of	dimenhydrinate	(DMH)	and	cinnarizine	(CIN)	in
presence	 of	 cinnarizine	 impurity	 (1‐(diphenylmethyl)piperazine)	 (IMP).	 In	 method	 A;
dimenhydrinate	was	determined	by	measuring	1D	amplitudes	at	292.0	nm	while	cinnarizine
and	its	impurity	were	determined	by	1DD	method	at	256.2	and	219.6	nm,	respectively,	using
standard	spectrum	of	20	µg/mL	of	dimenhydrinate	as	a	divisor.	Method	B	depends	on	dividing
spectrum	of	ternary	mixture	by	standard	spectrum	of	20	µg/mL	of	dimenhydrinate	and	then
cinnarizine	 and	 its	 impurity	 were	 determined	 in	 the	 obtained	 ratio	 spectrum	 by	 ratio
difference	method	using	the	difference	between	219.0	and	237.2	nm	and	between	230.0	and
264.0	nm,	respectively.	On	 the	other	hand	dimenhydrinate	could	be	determined	by	dividing
spectrum	 of	 ternary	mixture	 by	 standard	 spectrum	 of	 20	 µg/mL	 of	 cinnarizine	 and	 then	 it
were	 determined	 at	 the	 obtained	 ratio	 spectrum	 by	 ratio	 difference	 method	 using	 the
difference	 between	 216.8	 and	 232.8	 nm.	 Method	 C	 is	 the	 mean	 cantering	 of	 ratio	 spectra
method	 (MCR)	 where	 the	 amplitudes	 at	 234.8,	 240.0	 and	 233.6	 nm	 in	 the	 second	 mean
centering	 ratio	 spectra	were	 used	 for	 determination	 of	 dimenhydrinate,	 cinnarizine	 and	 its
impurity,	 respectively.	 The	 developed	methods	 were	 validated	 according	 to	 ICH	 guidelines
regarding	good	accuracy	and	precision,	and	they	were	successfully	applied	to	pharmaceutical
formulation	and	 laboratory	prepared	mixtures.	The	results	were	statistically	compared	with
those	obtained	by	reported	method	and	no	significant	difference	was	found.	
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1.	Introduction	
	
Dimenhydrinate;	 is	 chemically	 known	 as	 8‐chloro‐3,7‐
dihydro‐1,	3‐dimethyl‐1H‐purine‐2,6‐dione	compound	with	2‐
(diphenylmethoxy)‐N,N‐dimethylethanamine	 (1:1),	 it	 is	 the	
diphenhydramine	 salt	 of	 8‐chlorotheophylline	 [1]	 (Figure	 1).	
DMH	 has	 antihistaminic	 with	 antimuscarinic	 and	 significant	
sedative	effects.	It	is	mainly	used	as	an	antiemetic	drug	in	the	
prevention	and	treatment	of	motion	sickness	[2].	Cinnarizine;	
chemically	known	as	(E)‐1‐(diphenylmethyl)‐4‐(3‐phenylprop	
‐2‐enyl)	piperazine	[1]	(Figure	1),	it	is	a	piperazine	derivative	
with	 antihistaminic,	 sedative	 and	 calcium‐channel	 blocking	
activity.	 It	 is	 used	 for	 the	 symptomatic	 treatment	 of	 nausea,	
vertigo,	 treatment	 of	 motion	 sickness	 and	 cerebral	 vascular	
disorders	[2].	British	Pharmacopeia	[3]	stated	that	1‐(diphenyl	
methyl)	piperazine	is	cinnarizine	impurity,	it	is	also	known	as	
benzhydrylpiperazine,	[1]	(Figure	1).	
Cinnarizine	is	official	in	British	Pharmacopeia	(BP)	[3]	and	
European	 Pharmacopeia	 (EP)	 [4],	 both	 of	 them	 includes	
potentiometric	titration	for	estimation	of	CIN.	Dimenhydrinate	
is	 official	 in	 BP	 [3],	 EP	 [4]	 and	 United	 States	 Pharmacopeia	
(USP)	 [5],	 which	 includes	 potentiometric	 titration,	 argento‐
metric	titration	and	HPLC	method	for	estimation	of	DMH.	The	
combination	 of	 these	 two	 drugs	 is	 not	 official	 in	 any	
pharmacopoeia.		
	
(a)	
	
(b)	
	
(c)	
Figure	 1. Chemical	 structures	 of	 (a)	 cinnarizine,	 (b)	 dimenhydrinate,	 (c)	
diphenylmethyl	piperazine	(impurity).	
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Literature	 review	 shows	 that	 numbers	 of	 analytical	
methods	are	available	 for	estimation	of	both	the	drugs	either	
spectrophotometry	 including:	 Q‐absorbance	 ratio	 spectro‐
photometric	 method	 [6],	 simultaneous	 chemical	 equation	
method	 [7],	 derivative	 spectrophotometric	 method	 [8]	 and	
dual	 wavelength	 spectrophotometric	 method	 [9],	 or	 chro‐
matography	 including:	 validated	 HPTLC	 method	 [10]	 and	
HPLC‐method	[11,12].	
We	 have	 not	 come	 across	 any	 analytical	 methods	 for	
determination	 of	 both	 the	 drugs	 in	 presence	 of	 cinnarizine	
impurity.	 Either	 of	 these	 methods	 can	 be	 used	 for	 determi‐
nation	 of	 cinnarizine	 impurity.	 Therefore,	 the	 objective	 of	
work	 is	 to	 develop	 three	 accurate,	 sensitive	 and	 reliable	
spectrophotometric	 method	 for	 determination	 of	 cinnarizine	
and	dimenhydrinate	 in	presence	of	cinnarizine	 impurity	with	
high	sensitivity	and	 selectively	and	 to	 validate	 the	developed	
methods	according	to	ICH	guidelines	[13].	
	
2.	Experimental		
	
2.1.	Instrumentations	
	
A	 double	 beam	 UV‐visible	 spectrophotometer,	 Shimadzu,	
Japan,	Model	UV‐1601	PC	with	quartz	cell	of	1	cm	and	UV‐PC	
personal	 software	 version	 3.7	 was	 used.	 The	 spectral	 band	
width	is	2	nm	and	wavelength‐scanning	speed	2800	nm/min.	
Data	analysis	for	mean	centering	of	ratio	spectra	method	was	
performed	 using	 PLS‐Toolbox	 2.0	 running	 under	MATLAB®,	
version	6.5.	
	
2.2.	Materials	
	
2.2.1.	Pure	samples	
	
Pure	 samples	 of	 CIN	 and	 DMH	 were	 kindly	 supplied	 by	
Amoun	 Pharmaceutical	 Company,	 Cairo,	 Egypt	 with	 claimed	
purity	of	99.6	and	99.7%,	respectively,	according	to	manufac‐
turer	certificates	of	analysis.	While	cinnarizine	impurity	(IMP)	
was	 obtained	 from	 (Sigma‐Aldrich	 Chemie	 GmbH,	 Germany)	
with	 claimed	 purity	 of	 97%	 according	 to	 the	 manufacturing	
certificates	of	analysis.	
		
2.2.2.	Pharmaceutical	dosage	form		
	
Amocerebral®	 tablets	 (Batch	No.	 6221025030658)	were	
manufactured	 by	 Amoun	 Pharmaceutical	 Company,	 Cairo,	
Egypt.	Each	 tablet	 is	claimed	 to	contain	10	mg	of	CIN	and	20	
mg	of	DMH.		
	
2.2.3.	Solvents	
		
Methanol	 HPLC	 grade	 (Chromasolve®,	 Sigma‐Aldrich	
Chemie	GmbH,	Germany).	
	
2.2.4.	Solutions		
	
Stock	 solutions	 of	 CIN,	 DMH	 and	 IMP	 were	 prepared	 in	
methanol	 in	 the	 concentration	 of	 1	 mg/mL.	 They	 were	
prepared	by	weight	0.1	g	of	each	drug	in	three	separated	100	
mL	calibrated	flasks.	Working	solutions	of	CIN,	DMH	and	IMP	
were	prepared	in	methanol	in	the	concentration	of	100	µg/mL	
by	 separately	 diluting	 5	 mL	 of	 each	 stock	 solution	 in	 three	
separated	50	mL	volumetric	flask.	
	
3.	Methods	
	
3.1.	Linearity	
	
Accurate	 aliquots	 equivalent	 to	 30‐300,	 20‐400	 and	 20‐
200	µg	from	CIN,	DMH	and	IMP,	respectively,	were	taken	from	
their	 working	 solutions	 (100	 µg/mL)	 and	 transferred	 into	
three	 separate	 series	 of	 10	 mL	 volumetric	 flasks	 then	
completed	to	 the	mark	with	methanol.	Zero	order	absorption	
spectra	of	 the	prepared	samples	were	measured	 in	 the	range	
of	200‐400	nm	(Figure	2).	
	
 
 
Figure	2.	Zero	order	absorption	spectra	of	20	µg/mL	of	each	of	cinnarizine	
	.blank	a	as	methanol	using	(‐‐‐)	impurity	and	(…)	dimenhydrinate	,(ــــــ)
	
3.1.1.	Method	A	
	
Calibration	 curve	of	DMH	was	 constructed	by	plotting	 1D	
amplitudes	at	292.0	nm	(Δλ	=	2	and	scaling	factor	=	10)	versus	
the	corresponding	concentration	 in	 the	 range	of	2‐40	µg/mL.	
For	determination	of	CIN	and	IMP,	the	spectra	of	the	prepared	
samples	 in	 the	 range	 of	 3‐30	 and	 2‐20	 µg/mL,	 respectively,	
were	divided	by	standard	spectrum	of	20	µg/mL	of	DMH,	then	
first	 derivative	 of	 the	 obtained	 ratio	 spectra	 were	 obtained	
using	Δλ	=	2	and	scaling	factor	=	10.	1DD	amplitudes	at	256.2	
and	219.6	nm	were	obtained	from	which	calibration	graphs	for	
CIN	 and	 IMP,	 respectively,	were	 obtained	 and	 the	 regression	
equations	were	computed.	
	
3.1.2.	Method	B	
	
For	 determination	 of	 DMH,	 its	 absorption	 spectra	 were	
separately	divided	by	 the	 standard	 spectrum	of	 20	µg/mL	of	
CIN,	 then	 DMH	 was	 determined	 by	 measuring	 the	 ratio	
difference	at	216.8	and	232.8	nm	(at	which	CIN	and	IMP	have	
zero	difference).	While	for	determination	of	CIN	and	IMP	their	
absorption	 spectra	 were	 separately	 divided	 by	 the	 standard	
spectrum	of	20	µg/mL	of	DMH,	 then	CIN	was	determined	by	
measuring	 the	 ratio	 difference	 at	 219.0	 and	 237.2	 nm	 (at	
which	 DMH	 and	 IMP	 have	 zero	 difference).	 While	 IMP	 was	
determined	by	measuring	 the	 ratio	difference	between	230.0	
and	 264.0	 nm	 (zero	 difference	 for	 both	 DMH	 and	 CIN).	 The	
calibration	curves	for	DMH,	CIN	and	IMP	were	constructed	by	
plotting	 the	 ratio	 difference	 (for	 DMH,	 CIN	 and	 IMP)	 at	 the	
selected	 wavelengths	 against	 their	 corresponding	 concent‐
rations	and	the	regression	equations	were	obtained.	
	
3.1.3.	Method	C	(Mean	centering	of	ratio	spectra	
spectrophotometric	method)	
	
The	stored	spectra	of	three	components	were	exported	to	
Matlab	program	for	subsequent	calculation.	For	determination	
of	 CIN;	 the	 recorded	 spectra	 of	 CIN	 were	 divided	 by	 the	
standard	spectrum	of	DMH	(20	µg/mL)	to	obtain	the	first	ratio	
spectra	which	were	 then	mean	 centered.	These	 vectors	were	
then	 divided	 by	 the	 mean	 centered	 ratio	 of	 αIMP/αDMH	
(corresponding	 to	 standard	spectrum	of	20	µg/mL	each)	and	
the	mean	center	of	the	second	ratio	spectra	was	then	obtained.		
By	 the	 same	 way,	 the	 recorded	 spectra	 of	 DMH	 were	
divided	by	the	standard	spectrum	of	20	µg/mL	of	IMP	and	the	
obtained	ratio	spectra	were	then	mean	centered,	these	vectors	
(the	mean	 centered	 ratio	 spectra)	were	divided	by	 the	mean	
centered	 ratio	 of	 αCIN/αIMP	 (corresponding	 to	 standard	
spectrum	of	20	µg/mL	each)	to	obtain	the	second	ratio	spectra	
which	then	mean	centered.		
For	 determination	 of	 the	 IMP,	 the	 scanned	 spectra	 of	 its	
prepared	solutions	were	divided	by	the	standard	spectrum	of	
20	 µg/mL	 of	 DMH	 and	 the	 obtained	 ratio	 spectra	were	 then	
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mean	 centered.	 These	 vectors	 were	 divided	 by	 the	 mean	
centered	 ratio	 of	 αDMH	 /αCIN	 (corresponding	 to	 standard	
spectrum	of	20	µg/mL	each)	and	the	second	ratio	spectra	were	
then	 mean	 centered.	 The	 amplitudes	 of	 the	 second	 mean	
centered	ratio	spectra	at	240.0,	234.8	and	233.6	nm	were	used	
for	determination	of	CIN,	DMH	and	IMP,	respectively,	using	the	
corresponding	regression	equations.	
	
3.2.	Analysis	of	laboratory	prepared	mixtures	
	
Mixtures	containing	different	ratios	of	CIN,	DMH	and	 IMP	
(in	 the	 ratio	 of	 10‐80%	 of	 CIN)	 were	 prepared.	 The	 volume	
was	completed	with	methanol.	The	procedure	under	 linearity	
for	 each	method	was	 then	 followed	 and	 the	 concentration	 of	
each	 component	 was	 calculated	 from	 the	 corresponding	
regression	equations.	
	
3.3.	Application	to	pharmaceutical	formulation	
(Amocerebral®	tablets)	
	
Ten	 tablets	 of	 Amocerebral®	 tablets	 were	 weighed,	
powdered	and	mixed	well;	an	accurate	weight	of	the	powdered	
tablets	equivalent	 to	100	mg	of	CIN	and	200	mg	of	DMH	was	
transferred	 into	100	mL	volumetric	 flask.	75	mL	of	methanol	
was	added	and	sonicated	for	20	min;	then	filtered	into	100	mL	
volumetric	flask.	The	residue	was	washed	using	methanol	then	
the	 volume	 was	 completed	 with	 methanol	 to	 obtain	 stock	
solution	of	1	mg/mL.	From	which	sample	working	solution	of	
100	 µg/mL	 was	 prepared	 and	 then	 the	 procedure	 under	
linearity	 for	each	method	was	followed	and	concentrations	of	
DMH	and	CIN	were	calculated	using	the	previously	computed	
regression	equation.	
Standard	addition	has	been	carried	out	to	assess	validity	of	
the	 method	 by	 spiking	 the	 pharmaceutical	 formulation	 by	
known	amount	of	standard	drug	powder.	The	recovery	of	the	
added	 standards	 was	 then	 calculated	 after	 applying	 the	
proposed	methods.	
	
4.	Results	and	discussion		
	
Different	 analytical	 methods	 have	 been	 found	 in	 the	
literature	 for	 analysis	 of	 DMH	 and	 CIN	 binary	mixtures.	 But	
these	 methods	 cannot	 be	 applied	 for	 resolving	 the	 ternary	
mixture	 of	 DMH,	 CIN	 and	 IMP.	 As	 previously	 mentioned	 no	
published	 method	 was	 found	 in	 the	 literature	 for	 deter‐
mination	 of	 DMH	 and	 CIN	 in	 presence	 of	 CIN	 impurity.	 The	
work	in	this	manuscript	concerned	with	the	development	and	
validation	 of	 three	 accurate,	 selective	 and	 precise	 spectro‐
photometric	methods	 for	 resolving	 the	overlapped	spectra	of	
DMH,	 CIN	 and	 IMP	 (Figure	 2)	 with	minimum	 sample	 prepa‐
ration	and	data	manipulation.	
	
4.1.	Method	development	and	validation	
	
There	 are	 many	 factors	 that	 affect	 selectivity	 and	
sensitivity	of	the	developed	methods	such	as:	the	used	solvent,	
the	divisor	concentration	and	the	chosen	wavelength.	Different	
solvents	 were	 tried	 such	 as	 methanol,	 ethanol,	 acetonitrile,	
water,	 0.1	 N	 HCl	 and	 0.1	 N	 NaOH.	 Regarding	 method	 selec‐
tivity,	methanol	was	the	solvent	of	choice.	
Since	 the	 divisor	 and	 its	 concentration	 are	 greatly	 effect	
method	 selectivity,	 so	 different	 divisors	 with	 different	
concentrations	 were	 tried	 using	 of	 standard	 spectrum	 of	 20	
µg/mL	DMH	for	method	A,	B	and	C;	20	µg/mL	CIN	for	method	
B,	C	and	20	µg/mL	IMP	for	method	C	gave	the	best	results.	
Selections	 of	 wavelengths	 play	 important	 rule	 during	
development	 and	 optimization	 of	 method	 B.	 Different	
wavelength	pairs	were	 tested	where	 the	wavelength	pairs	 of	
216.8	and	232.8	nm,	219.0	and	237.4	nm	and	230.0	and	264.0	
nm	were	 the	 pairs	 of	 chosen	 for	 determination	 of	 DMH,	 CIN	
and	IMP,	respectively.	
4.1.1.	Method	A	
	
In	 this	 method,	 DMH	 could	 be	 determined	 by	 first	
derivative	 (1D)	 spectrophotometric	method	 using	 Δλ	 =	 2	 nm	
and	 scaling	 factor	 =	 10	 then	 measuring	 the	 peak	 amplitude	
values	at	292	nm,	Figure	3.	On	the	other	hand,	the	absorption	
spectra	 of	 different	 concentrations	 of	 CIN	 and	 IMP	 were	
recorded	 in	 the	 wavelength	 range	 of	 200‐400	 nm.	 The	
recorded	spectra	were	divided	by	the	standard	spectrum	of	20	
µg/mL	 DMH	 and	 the	 ratio	 spectra	 were	 obtained,	 then	 first	
derivative	 of	 these	 ratio	 spectra	were	 obtained	 using	 Δλ	 =	 2	
nm	 and	 scaling	 factor	 =	 10	 and	 peak	 amplitudes	 were	
measured	at	256.2	and	219.6	nm	for	CIN	and	IMP,	respectively,	
(Figure	4).	
	
	
	
Figure	3.	 First	 derivative	 spectra	 of	 20	 µg/mL	 of	 each	 of	 cinnarizine	 (…),	
dimenhydrinate	(‐‐‐)	and	impurity	(ــــ)	using	methanol	as	a	blank.	
	
	
	
	
Figure	4.	 First	derivative	of	 ratio	spectra	of	20	µg/mL	of	each	cinnarizine	 		
(‐‐‐),	dimenhydrinate	(ـــــ)	and	impurity	(…)	using	standard	spectrum	of	20	
µg/mL	of	dimenhydrinate	as	a	divisor	and	methanol	as	a	blank.	
	
Calibration	 curves	 relating	 the	 peak	 amplitude	 values	 at	
the	 selected	 wavelength	 versus	 the	 corresponding	
concentration	of	DMH,	CIN	and	IMP	in	the	concentration	range	
of	 2‐40,	 3‐30,	 2‐20	 µg/mL,	 respectively,	 from	 which	 the	
following	regression	equations	were	computed,	Table	1.	
	
Y1	=	0.0166	×	C[DMH]	+	0.0045,	r	=	0.9999	 	 (1)	
	
Y2	=	0.2361	×	C[CIN]	+	0.1112,	r	=	0.9999		 	 (2)	
	
Y3	=	0.0540	×	C[IMP]	+	0.0260,	r	=	0.9999	 	 (3)	
	
where	 Y1,	 Y2	 and	Y3	 are	 peak	 amplitudes	 for	DMH,	CIN	 and	
IMP,	 respectively,	 at	 selected	 wavelengths,	 C	 is	 the	 concent‐
ration	in	µg/mL	and	r	is	the	correlation	coefficient.	
	
4.1.2.	Method	B	
	
This	 method	 depended	 on	 using	 the	 ratio	 difference	
method	 which	 has	 the	 same	 principle	 as	 dual	 wavelength	
spectrophotometric	 method.	 The	 principle	 of	 this	 method	 is	
that	 the	 ratio	 difference	 at	 two	 wavelengths	 in	 the	 ratio	
spectra	 is	 directly	 proportional	 to	 the	 concentration	 of	 the	
component	of	interest	where	the	other	components	show	zero	
difference	 at	 the	 selected	 wavelengths.	 Ratio	 difference	
method	 has	 advantages	 of	 being	 able	 to	 resolve	 ternary	 and	
quaternary	mixtures	and	also	it	eliminate	derivative	steps	and	
so	signal	to	noise	ratio	is	enhanced.		
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Table	1.	Assay	parameters	and	method	validation	for	the	determination	of	pure	sample	of	CIN,	DMH	and	IMP	by	the	proposed	spectrophotometric	methods.	
IMP	DMHCINParameter	
		Method	A	
2‐20 2‐403‐30Calibration	range	(µg/mL) 
0.0540 0.01660.2361Slope 
0.0260 0.00450.0111Intercept 
0.9999 0.99990.9999Correlation	coefficient 
100.27±0.670 100.05±0.457100.21±0.864Accuracy	(Mean±SD) 
   Precision 
1.25 1.641.74Repeatability	a 
1.70 1.841.36Intermediate	precision	b 
99.90±1.331 100.30±1.764100.70±0.953Specificity 
0.42 0.480.93LOD	c	(µg/mL) 
1.27 1.472.85LOQ	c	(µg/mL) 
		Method	B	
2‐20 2‐403‐30Calibration	range	(µg/mL) 
0.0366 0.04530.1525Slope 
0.0060 0.09550.0592Intercept 
0.9998 0.99980.9999Correlation	coefficient 
99.92±0.903 99.98±0.771100.06±1.217Accuracy	(Mean±SD) 
   Precision 
1.14 1.580.89Repeatability	a 
1.67 1.081.03Intermediate	precision	b 
99.90±0.863 100.09±1.076	100.49±0.919Specificity 
0.48 0.580.95LOD	c	(µg/mL) 
1.65 1.872.91LOQ	c	(µg/mL) 
			Method	C	
2‐20 2‐403‐30Calibration	range	(µg/mL) 
8.4036 3.95731.2824Slope 
2.5860 4.57440.0269Intercept 
0.9998 0.99980.9999Correlation	coefficient 
101.17±1.326 100.	17±1.315100.05±0.577Accuracy	(Mean±SD) 
   Precision 
0.97 1.051.85Repeatability	a 
1.10 1.220.92Intermediate	precision	b 
100.14±1.177 99.60±1.404100.12±1.237Specificity 
0.60 0.460.87LOD	c	(µg/mL) 
1.90 1.452.74LOQ	c	(µg/mL) 
a	The	intraday	(n=3),	average	of	three	different	concentrations	repeated	three	times	daily.	
b	The	interday	(n=3),	average	of	three	different	concentrations	repeated	three	times	in	three	successive	days.	
c	Limit	of	detection	(3.3×SD/Slope)	and	limit	of	quantitation	(10×SD/Slope). 
	
	
Choosing	 of	 wavelength	 pairs	 play	 important	 rule	 in	
method	 selectivity,	 hence	 different	 pairs	 were	 tested.	
Measuring	 the	 difference	 between	 216.8‐232.8	 nm,	 219.0‐
237.2	nm	and	230.0‐264.0	nm	gave	the	best	results.	
The	 absorption	 spectra	 of	 DMH,	 CIN	 and	 IMP	 were	
separately	 divided	 by	 standard	 spectrum	 of	 20	 µg/mL	 CIN	
(Figure	5).	So	DMH	was	determined	using	the	ratio	difference	
between	216.8‐232.8	nm	in	the	obtained	ratio	spectra.	On	the	
other	hand	The	absorption	spectra	of	CIN,	DMH	and	IMP	were	
separately	 divided	 by	 standard	 spectrum	 of	 20	 µg/mL	 DMH	
(Figure	 6).	 So,	 there	 were	 determined	 using	 the	 ratio	 differ‐
rence	between	219.0‐237.2	nm	and	230.0‐264.0	nm,	 respect‐
tively,	in	the	obtained	ratio	spectra,	Figure	6.	
	
	
	
Figure	 5.	 Division	 spectra	 of	 20	 µg/mL	 of	 each	 of	 cinnarizine	 	,(ـــــ)
dimenhydrinate	 (…)	 and	 impurity	 (‐‐‐)	 using	 standard	 spectrum	 of	 20	
µg/mL	of	cinnarizine	as	a	divisor	and	methanol	as	a	blank.	
	
Calibration	 graphs	 were	 obtained	 by	 plotting	 the	
amplitudes	difference	 at	 the	 selected	wavelengths	versus	 the	
corresponding	 concentrations	 from	 which	 regression	
equations	were	computed	and	found	to	be:	
	
Y1	=	0.0272	×	C[DMH]	+	0.0034,	r	=	0.9999	 	 (4)	
Y2	=	0.1525	×	C[CIN]	+	0.0592,	r	=	0.9999	 	 (5)		
	
Y3	=	0.0366	×	C[IMP]	+	0.0060,	r	=	0.9998		 	 (6)	
	
Where	Y1,	Y2	and	Y3	are	 the	amplitudes	values	or	difference	
values	 at	 the	 selected	wavelengths,	 C	 is	 the	 concentration	 in	
µg/mL	and	r	is	the	correlation	coefficient.	
	
	
	
Figure	 6.	 Division	 spectra	 of	 20	 µg/mL	 of	 each	 of	 cinnarizine	 (…),	
dimenhydrinate	 (‐‐‐)	 and	 impurity	 	(ـــــ) using	 standard	 spectrum	 of	 20	
µg/mL	of	dimenhydrinate	as	a	divisor	and	methanol	as	a	blank.	
	
4.1.3.	Method	C	
	
The	proposed	MCR	method	is	based	on	the	mean	centering	
of	ratio	spectra.	This	method	was	applied	for	resolving	binary	
and	 ternary	mixtures	 in	 the	 complex	 samples	with	 unknown	
matrices	 and	 it	 eliminates	 signal	 to	 noise	 ratio	 and	
derivatization	step.	The	effect	of	divisor	concentration	on	the	
selectivity	of	this	method	has	been	tested	in	order	to	optimize	
the	developed	method.	
Different	concentrations	of	CIN,	DMH	and	IMP	were	tested.	
It	 was	 found	 that	 20	 µg/mL	 of	 DMH,	 CIN	 and	 IMP	were	 the	
suitable	divisors.	
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Table	2.	Assay	result	for	the	determination	of	CIN,	DMH	and	IMP	in	synthetic	mixtures	using	the	proposed	spectrophotometric	methods.	
Ratio	of	CIN:DMH	 %	Impurity	 Concentration	taken	(µg/mL)	 %	Recovery	
CIN	 DMH IMP CIN DMH IMP	
Method	A	 	 	 	 	 	 	 	
3:1	 10	 27	 10	 3	 100.97	 101.25	 98.64	
1:2	 30	 14	 40 6 99.84 101.51	 100.04
1:1	 40	 9	 30 6 101.70 98.06 99.69	
1:1	 50	 10	 20 10 101.35 101.59	 101.30
1:1	 70	 6	 20 14 101.12 101.41	 101.50
1:2	 80	 4	 10 16 99.24 98.00 98.26	
Mean±SD	 	 100.14±1.177 99.60±1.404 100.12±1.237
Method	B	 	 	 	
3:1	 10	 27	 10 3 99.36 101.36	 100.26
1:2	 30	 14	 40 6 101.21 99.54 101.11
1:1	 40	 9	 30 6 99.83 99.31 98.66	
1:1	 50	 10	 20 10 99.99 99.45 99.26	
1:1	 70	 6	 20 14 100.78 101.59	 99.80	
1:2	 80	 4	 10	 16	 101.78	 99.31	 100.32	
Mean±SD	 	 99.90±0.863 100.09±1.076 100.49±0.919
Method	C	 	 	 	
3:1	 10	 27	 10 3 100.39 98.13 100.38
1:2	 30	 14	 40 6 99.63 98.26 98.68	
1:1	 40	 9	 30	 6	 101.06	 99.51	 99.39	
1:1	 50	 10	 20	 10	 101.87	 99.23	 101.28	
1:1	 70	 6	 20	 14	 99.34	 100.83	 101.68	
1:2	 80	 4	 10	 16	 98.45	 101.66	 99.43	
Mean	±	SD	 	 99.90±1.331 100.30±1.764 100.70±0.953
	
	
For	 determination	 of	 CIN,	 the	 recorded	 spectra	 of	 CIN	
were	divided	by	 the	standard	spectrum	of	20	µg/mL	DMH	to	
obtain	the	first	ratio	spectra	which	were	then	mean	centered.	
These	vectors	were	then	divided	by	the	mean	centered	ratio	of	
αDMH	 /αIMP	 (corresponding	 to	 standard	 spectrum	 of	 20	
µg/mL	 each)	 and	 the	 mean	 centering	 of	 the	 second	 ratio	
spectra	 was	 then	 obtained.	 By	 the	 same	 way,	 the	 recorded	
spectra	of	DMH	were	divided	by	the	standard	spectrum	of	IMP	
(20	 µg/mL)	 and	 the	 obtained	 ratio	 spectra	 were	 then	mean	
centered,	these	vectors	(the	mean	centered	ratio	spectra)	were	
then	 divided	 by	 the	 mean	 centered	 ratio	 of	 αIMP/αCIN	
(corresponding	 to	 standard	 spectrum	 of	 20	 µg/mL	 each)	 to	
obtain	the	second	ratio	spectra	which	then	mean	centered.	For	
determination	 of	 IMP,	 the	 scanned	 spectra	 of	 its	 prepared	
solutions	were	divided	by	the	standard	spectrum	of	20	µg/mL	
of	 DMH	 and	 the	 obtained	 spectra	 were	 then	mean	 centered.	
These	 vectors	 were	 divided	 by	 the	 mean	 centered	 ratio	 of	
αDMH/αCIN	 (corresponding	 to	 standard	 spectrum	 of	 20	
µg/mL	 each)	 and	 the	 second	 spectra	 ratio	 were	 then	 mean	
centered.	 The	 amplitudes	 of	 the	 second	mean	 centered	 ratio	
spectra	 at	 240.0,	 234.8	 and	 233.6	 nm	 were	 used	 for	
determination	 of	 CIN,	 DMH	 and	 IMP,	 respectively.	 The	
amplitudes	 were	 measured	 and	 plotted	 against	 the	
corresponding	 concentration	 of	 each	 component	 to	 compute	
their	respective	regression	equations	(Figure	7‐9).	Linearity	of	
the	proposed	method	was	evaluated	and	it	was	evident	in	the	
range	 of	 3‐30,	 2‐40	 and	 2‐20	 µg/mL	 for	 CIN,	 DMH	 and	 IMP,	
respectively.	 The	 regression	 equations	 for	 each	 component	
were	calculated	as	given	in	Table	1	and	found	to	be:	
	
Y1	=	3.9573	×	C[DMH]	‐	4.5744,	r	=	0.9998	 	 (7)		
	
Y2	=	1.2824	×	C[CIN]	+	0.2696,	r	=	0.9999	 	 (8)		
	
Y3	=	8.4036	×	C[IMP]	‐	2.5860,	r	=	0.9998	 	 (9)		
	
where	 Y1,	 Y2	 and	 Y3	 are	 the	 peak	 amplitudes	 value	 at	 the	
selected	wavelengths,	C	is	the	concentration	in	µg/mL	and	r	is	
the	correlation	coefficient.	 	
The	selectivity	of	the	proposed	methods	was	evaluated	by	
analysis	of	different	 laboratory	prepared	mixtures	containing	
different	 ratios	 of	 the	 studied	 components,	 where	 the	 mean	
percentage	 recoveries	 for	 DMH,	 CIN	 and	 IMP	 were	
99.60±1.404,	 100.14±1.177	 and	 100.12±1.237,	 respectively,	
for	method	A,	 100.09±1.076,	 99.90±0.863	 and	 100.49±0.919,	
respectively,	 for	 method	 B	 and	 100.30±1.764,	 99.90±1.331	
and	100.70±0.953,	respectively,	for	method	C,	Table	2.	
	
	
	
Figure	7. Mean	 centered	 ratio	 spectra	 of	 cinnarizine	 (3‐30	 µg/mL)	 using	
methanol	as	a	blank.	
	
	
	
Figure	 8.	 Mean	 centered	 ratio	 spectra	 of	 dimenhydrinate	 (2‐40	 µg/mL)	
using	methanol	as	a	blank.	
	
The	 developed	 spectrophotometric	 methods	 were	 also	
applied	 for	 determination	 of	 CIN	 and	DMH	 in	Amocerebral®	
tablets	 and	 satisfactory	 results	were	 obtained	 (Table	 3).	 The	
validity	 of	 the	 methods	 was	 further	 assessed	 by	 applying	
standard	 addition	 technique	 which	 also	 confirmed	 the	
accuracy	 of	 the	 proposed	 methods	 (Table	 3).	 The	 results	
obtained	by	applying	the	proposed	methods	were	statistically	
compared	with	those	obtained	by	applying	the	reported	HPLC	
method	for	determination	of	Amocerebral®	tablets.		
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Table	 3.	Determination	 of	 CIN	 and	 DMH	 in	 their	 pharmaceutical	 formulation	 by	 the	 proposed	 spectrophotometric	 methods	 and	 application	 of	 standard	
addition	technique.	
Found	%	Recovery,	%Added	(µg/mL)Methods 
	
Pharmaceutical	formulation	
DMHCIN	DMHCINDMHCIN	
105.77±1.601103.14±1.079	99.39100.7855	Method	A	Amocerebral	plus	®	tablets	
CIN,	10	mg	
DMH,	20	mg	
101.5099.34107 
98.59101.341510 
100.75101.222015 
100.06±1.311100.67±0.921Mean	±	SD
103.79±1.396 104.27±1.628 101.3298.0755	Method	B 
100.9999.7410	7	
98.96101.881510	
100.16101.892015	
100.36±1.049100.40±1.852 Mean	±	SD
104.67±1.284 104.46±1.418 101.63100.95	5	5	Method	C	
 101.1999.36107	
98.27100.021510	
99.49101.872015 
100.152±1.551100.55±1.098 Mean	±	SD
	
	
Table	4.	Statistical	comparison	of	the	results	obtained	by	applying	the	proposed	spectrophotometric	methods	and	the	reported	methods	for	analysis	of	CIN	and	
DMH	in	their	pharmaceutical	formulation.		
Reported	method	[12] Method	CMethod	BMethod	A Parameter 
DMHCIN DMHCINDMHCIN DMH CIN 
103.72 106.16 104.67104.46103.79104.27105.77 103.14 Mean 
1.783 1.747 1.2841.4181.3961.628 1.601 1.079 SD 
3.815 3.664 1.6482.0112.3403.183	2.564	1.164	Variance	
6 6 6666 6 6 N 
‐ ‐0.99361.74250.61331.76961.9861 1.8595 t‐test	a	
‐ ‐0.43211.82160.07001.15130.6720 3.1475 F‐value	a	
a	The	values	in	parenthesis	are	corresponding	to	the	theoretical	values	of	t	and	F	(p	=	0.05).	
	
	
The	values	of	the	obtained	F	and	t‐tests	were	less	than	the	
calculated	 ones	 confirming	 that	 the	 difference	 between	 the	
developed	 methods	 and	 the	 reported	 one	 is	 non‐significant,	
Table	4.	
	
	
	
Figure	 9.	 Mean	 centered	 ratio	 spectra	 of	 impurity	 (2‐20	 µg/mL)	 using	
methanol	as	a	blank.	
	
4.2.	Method	validation		
	
Validation	of	the	methods	was	carried	out	according	to	ICH	
recommendations	[13].	
	
4.2.1.	Linearity	and	range		
	
The	 linearity	 of	 the	 proposed	methods	was	 evaluated	 by	
analyzing	 different	 concentrations	 of	 CIN,	 DMH	 and	 IMP	 in	
triplicates.	 For	 the	 developed	 methods,	 Beer‐Lambert’s	 was	
obeyed	 in	 the	 range	 of	 3‐30,	 2‐40	 and	 2‐20	 µg/mL	 for	 CIN,	
DMH	 and	 IMP,	 respectively.	 The	 values	 of	 correlation	
coefficients	were	close	 to	unity	 indicating	good	 linearity.	The	
regression	 parameters	 like	 the	 slope,	 intercept	 and	 the	
correlation	 coefficient	 were	 calculated	 and	 are	 presented	 in	
Table	1.	
	
	
	
4.2.2.	Accuracy		
	
Accuracy	 of	 the	 proposed	methods	was	 calculated	 as	 the	
percentage	 recoveries	 of	 pure	 samples	 of	 the	 studied	 drugs.	
The	 concentrations	 were	 calculated	 from	 the	 corresponding	
regression	equations,	Table	1.	Accuracy	was	 further	assessed	
by	applying	the	standard	addition	technique	to	Amocerebral®	
tablets,	 where	 good	 recoveries	 were	 obtained	 revealing	 that	
there	was	no	interference	from	excipients,	Table	3.	
	
4.2.3.	Precision	
	
Repeatability:	 Three	 concentrations	 7,	 15,	 25	 µg/mL	 of	
CIN;	 20,	 30,	 40	 µg/mL	 of	 DMH	 and	 7,	 12,	 20	 µg/mL	 of	 IMP	
were	 analyzed	 three	 times	 intra‐daily	 using	 the	 proposed	
methods.	 Good	 results	 and	 acceptable	 standard	 deviations	
(SDs)	were	obtained,	Table	1.	
Intermediate	 precision:	 The	 previous	 methods	 were	
repeated	inter‐daily	on	three	different	days	for	the	analysis	of	
the	 chosen	 concentrations.	 Good	 results	 and	 acceptable	 SDs	
were	 obtained;	 good	 results	were	 obtained	 and	presented	 in	
Table	1.	
	
4.2.4.	Selectivity		
	
Selectivity	 of	 the	 proposed	methods	was	 assessed	 by	 the	
analysis	 of	 different	 synthetic	 laboratory	 prepared	 mixtures	
containing	different	 ratios	 of	 CIN,	DMH	and	 IMP	within	 their	
linearity	ranges;	good	results	were	obtained	and	presented	in	
Table	1.	
	
4.2.5.	Detection	and	quantitation	limits	
	
These	approaches	based	on	the	SD	of	the	response	and	the	
slope	 were	 used	 for	 determining	 the	 detection	 and	
quantitation	 limits	 where	 LOD	 =	 3.3×SD/slope	 and	 LOQ	 =	
10×SD/slope,	Table	1.	
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5.	Conclusion	
	
The	 developed	 methods	 have	 advantages	 over	 the	
published	 methods	 in	 being	 used	 for	 analysis	 of	 cinnarizine	
and	 dimenhydrinate	 in	 the	 presence	 of	 cinnarizine	 impurity.	
These	methods	were	simple,	rapid,	and	cost	effective	and	data	
processing	steps	are	not	time	consuming.	These	spectrophoto‐
metric	 methods	 can	 be	 regarded	 as	 a	 useful	 alternative	 to	
chromatographic	 techniques	 in	 the	 routine	 quality	 control	
analysis	 of	 pharmaceutical	 formulations	 allowing	 rapid	
determination	 at	 relatively	 low	 cost.	 The	developed	methods	
can	 be	 easily	 and	 conveniently	 adopted	 for	 routine	 quality	
control	analysis	of	CIN,	DMH	and	IMP.	
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